A new nasal spray has been found effective in treating people with depression who are often unable to relieve their symptoms despite trying other anti-depressants says a study. The study published in the American Journal of Psychiatry is one of the key findings that led to the recent US Food and Drug Administration (FDA) approval of esketamine nasal spray in conjunction with an oral antidepressant for use in people with treatment-resistant depression. This trial of esketamine was one of the pivotal trials in the FDA's review of this treatment for patients with treatment resistant depression. Not only was adjunctive esketamine
